Back to News
Market Impact: 0.34

Here are Friday's biggest analyst calls: Nvidia, Alphabet, Dell, Cisco, Netflix, Texas Roadhouse, J.M. Smucker & more

RXOCSCOBWXTEVRCBACLOOPMSNVDAANETVIKGSORICJPMTXRHEBCDELLSOLVHSBCDBRY
Analyst InsightsCorporate Guidance & OutlookCorporate EarningsCompany FundamentalsTechnology & InnovationArtificial IntelligenceTransportation & LogisticsHealthcare & BiotechInfrastructure & DefenseConsumer Demand & Retail
Here are Friday's biggest analyst calls: Nvidia, Alphabet, Dell, Cisco, Netflix, Texas Roadhouse, J.M. Smucker & more

Wall Street produced a broadly positive set of calls, led by upgrades on RXO, Cisco with a new $137 target, CH Robinson, Arista Networks, First Energy, Texas Roadhouse, and several initiations including Vertiv at Buy with a $500 target. Analysts highlighted AI infrastructure momentum for Cisco, Nvidia, Dell, Vertiv and Applied Materials, while healthcare and transport names such as Aveanna, BWX Technologies, and RXO also saw constructive notes. The only notable negative was Morgan Stanley’s downgrade of Viking Holdings to Equal Weight after earnings, citing valuation and a more balanced risk/reward.

Analysis

The common thread is not just positive analyst action, but a re-rating of names with operating leverage to scarce capacity: AI infrastructure, transmission, defense programs, and asset-light logistics. That favors businesses where incremental demand can flow through without major capex spikes — CSCO, NVDA, ANET, DELL, VRT-by-proxy, BWXT, FE, RXO, and CHRW — while pressuring “good enough” compounders where valuation has already pulled forward, as seen in VIK. The second-order effect is a likely widening dispersion within industrials and tech: AI spend is concentrating into a smaller set of vendors, so winners should keep taking share even if overall IT budgets merely hold steady. The most interesting setup is the juxtaposition of cyclical recovery and idiosyncratic acceleration. Transportation upgrades on RXO and CHRW suggest the sell-side is now looking past near-term freight weakness toward 2026 brokerage normalization, which can produce sharp upside if pricing inflects earlier than expected. In healthcare, AVAH and SOLV are being framed as quality/special-situation stories, but those reratings typically require a cleaner execution runway; if reimbursement or labor costs wobble, the multiple expansion case can unwind quickly over 1-2 quarters. Consensus may be underestimating how self-reinforcing the AI hardware cycle has become. NVDA, DELL, and ANET are not just beneficiaries of higher capex; they also gain from vendor lock-in, network effects, and accelerating product refresh cycles, which means the revenue duration may be longer than the market’s current one-year framing. By contrast, the contrarian risk in names like TXRH and FE is that the market is leaning too hard into “overdone concerns” narratives — if input costs or rates stop improving, the upside can stall even if the fundamental story remains intact.